Park Chan Hum, Tanaka Takashi, Akimoto Yoshie, Jeon Jin Pyeong, Yokozawa Takako
Institute of New Frontier Research Team, Hallym Clinical and Translational Science Institute, Hallym University, Chuncheon 24252, Republic of Korea.
Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8521, Japan.
Medicines (Basel). 2023 Mar 21;10(3):24. doi: 10.3390/medicines10030024.
Hachimijiogan (HJG) and Bakumijiogan (BJG), two derivative prescriptions of Rokumijiogan (RJG), were selected to investigate their renoprotective potential in the 5/6 nephrectomized (5/6Nx) rat model. Rats were treated with HJG and BJG orally at 150 mg/kg body weight/day once daily for 10 weeks after resection of 5/6 of the renal volume, and their renoprotective effects were compared with 5/6Nx vehicle-treated and sham-operated control rats. Improvements in renal lesions, glomerulosclerosis, tubulointerstitial injury, and arteriosclerotic lesions estimated by histologic scoring indices in the HJG-treated group were compared with those in the BJG-treated group. HJG- and BJG-treated groups ameliorated the renal function parameters. Elevated levels of renal oxidative stress-related biomarkers were reduced, while decreased antioxidant defence systems (superoxide dismutase and the glutathione/oxidized glutathione ratio) were increased in the HJG-treated group rather than the BJG-treated group. In contrast, BJG administration significantly reduced expression of the inflammatory response through oxidative stress. The HJG-treated group showed a decrease in inflammatory mediators through the JNK pathway. To gain a deeper understanding of their therapeutic action, the effects of the main components detected in HJG and BJG were evaluated using the LLC-PK renal tubular epithelial cell line, which is the renal tissue most vulnerable to oxidative stress. Corni Fructus and Moutan Cortex-originated compositions afforded important protection against oxidative stress induced by peroxynitrite. From our described and discussed analyses, it can be concluded that RJG-containing prescriptions, HJG and BJG are an excellent medicine for chronic kidney disease. In the future, appropriately designed clinical studies in people with chronic kidney disease are necessary to evaluate the renoprotective activities of HJG and BJG.
八味地黄丸(HJG)和六味地黄丸(BJG)是六味地黄丸(RJG)的两种衍生方剂,被选来研究它们在5/6肾切除(5/6Nx)大鼠模型中的肾脏保护潜力。在切除5/6的肾体积后,大鼠每天口服150mg/kg体重的HJG和BJG,持续10周,然后将它们的肾脏保护作用与接受5/6Nx赋形剂处理的大鼠以及假手术对照组大鼠进行比较。通过组织学评分指标评估HJG治疗组的肾脏病变、肾小球硬化、肾小管间质损伤和动脉硬化病变的改善情况,并与BJG治疗组进行比较。HJG和BJG治疗组改善了肾功能参数。HJG治疗组中升高的肾脏氧化应激相关生物标志物水平降低,而降低的抗氧化防御系统(超氧化物歧化酶和谷胱甘肽/氧化型谷胱甘肽比值)升高,BJG治疗组则不然。相比之下,BJG给药通过氧化应激显著降低了炎症反应的表达。HJG治疗组通过JNK途径使炎症介质减少。为了更深入了解它们的治疗作用,使用LLC-PK肾小管上皮细胞系评估了HJG和BJG中检测到的主要成分的作用,该细胞系是最易受氧化应激影响的肾组织。山茱萸和牡丹皮来源的成分对过氧亚硝酸盐诱导的氧化应激提供了重要保护。从我们所描述和讨论的分析中可以得出结论,含RJG的方剂HJG和BJG是治疗慢性肾病的良药。未来,有必要在慢性肾病患者中进行适当设计的临床研究,以评估HJG和BJG的肾脏保护活性。